|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Prothera_Biologics
|
|
gptkbp:ceo
|
Jon P. Stone
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Asia
gptkb:North_America
gptkb:European_Medicines_Agency
gptkb:Bio_Cryst_Pharmaceuticals,_Inc.
gptkb:Research_Institute
Phase 1
Phase 2
Phase 3
BC X1942
BC X7353
|
|
gptkbp:collaborations
|
gptkb:Duke_University
gptkb:University_of_Alabama_at_Birmingham
|
|
gptkbp:employees
|
Approximately 200
|
|
gptkbp:focus_area
|
Rare diseases
|
|
gptkbp:founded
|
gptkb:1986
|
|
gptkbp:founder
|
Jon P. Stone
|
|
gptkbp:grants
|
NIH Grant
FDA Grant
NIAID Grant
|
|
gptkbp:headquarters
|
gptkb:Birmingham,_Alabama
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bio Cryst Pharmaceuticals, Inc.
|
|
gptkbp:invention
|
US Patent 9,012,345
US Patent 10,123,456
US Patent 8,481,992
|
|
gptkbp:investment
|
$100 million
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market_cap
|
$500 million
|
|
gptkbp:notable_products
|
gptkb:Berotralstat
gptkb:Peramivir
|
|
gptkbp:partnership
|
gptkb:temple
gptkb:Bristol-Myers_Squibb
gptkb:Hikma_Pharmaceuticals
gptkb:Shionogi_&_Co.
|
|
gptkbp:products
|
Oral medication
Injectable
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:research
|
Dr. William P. Mc Gowan
|
|
gptkbp:research_focus
|
gptkb:Influenza
Antiviral drugs
Orphan drugs
Hereditary angioedema
|
|
gptkbp:revenue
|
$50 million
|
|
gptkbp:subsidiary
|
Bio Cryst Pharmaceuticals (Canada) Inc.
Bio Cryst Pharmaceuticals (UK) Ltd.
|
|
gptkbp:symbol
|
BCRX
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.biocryst.com
|
|
gptkbp:bfsParent
|
gptkb:Bio_Cryst_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|